3 h. ago China’s Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion

China’s Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion  The Wall Street Journal

Economics

6 h. ago Takeda Inks Deal With China’s Innovent to Develop Cancer Drugs

Takeda Inks Deal With China’s Innovent to Develop Cancer Drugs  Bloomberg

Events

49 h. ago China’s Akeso gets share boost as data shows cancer drug’s benefits

Shares of Chinese drug firm Akeso – likened by some Western media outlets to artificial intelligence start-up DeepSeek – rose after the company unveiled clinical-trial data showing that its lung-cancer drug outperformed a highly effective existing treatment. The data showed that ivonescimab had “a decisive and strong positive outcome with both significant and clinically meaningful benefits”, Akeso said in a filing with the Hong Kong stock exchange on Monday. The drug, used along with...

Events

5 d. ago Hansoh and Leads Biolabs clinch US$2.5 billion in global drug licensing deals

Two Chinese drug developers have signed licensing deals that could yield as much as US$2.5 billion in performance-based payments, underscoring growing international confidence in China’s life sciences sector. Hansoh Pharmaceutical Group has agreed to license global rights – excluding mainland China, Hong Kong, Macau and Taiwan – to develop and market a colon cancer drug candidate to F Hoffmann-La Roche, a unit of Swiss-based biotech giant Roche. Hansoh, a major psychotropic and cancer drugs...

Economics

5 d. ago China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche

China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche  Reuters

Economics

7 d. ago Cancer drug specialist to set up HK$600 million production line in Hong Kong

A Hong Kong company specialised in producing drugs for cancer treatment has been granted financial support from the government to set up its production line in the city’s science park under a scheme to accelerate new industrialisation. Advanced Isotopes Technology Asia announced on Tuesday that it would invest HK$600 million (US$77.12 million) to set up three production lines at Tai Po InnoPark, under the Hong Kong Science and Technology Parks Corporation (HKSTP), with around HK$140 million...

Economics

2 w. ago Chinese healthcare, biotech firms flock to Hong Kong for IPOs

Eleven Chinese healthcare and biotechnology companies filed applications to list on the Hong Kong stock exchange in the last two days of September, taking advantage of an ongoing investment boom in the sector. The best-known names among them are online healthcare services firm We Doctor Holdings, Sichuan Biokin Pharmaceutical – known for a US$8.4 billion licensing deal with US-based Bristol Myers Squibb (BMS) – and profitable cancer-drug developer Betta Pharmaceuticals. Other initial public...

Economics